Cargando…

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor

Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dotsu, Yosuke, Yamaguchi, Hiroyuki, Fukuda, Minoru, Suyama, Takayuki, Honda, Noritaka, Umeyama, Yasuhiro, Taniguchi, Hirokazu, Gyotoku, Hiroshi, Takemoto, Shinnosuke, Tagawa, Ryuta, Ogata, Ryosuke, Tomono, Hiromi, Shimada, Midori, Senju, Hiroaki, Nakatomi, Katsumi, Nagashima, Seiji, Soda, Hiroshi, Ikeda, Hiroaki, Ashizawa, Kazuto, Mukae, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464789/ https://www.ncbi.nlm.nih.gov/pubmed/34575334 http://dx.doi.org/10.3390/jcm10184221

Ejemplares similares

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
por: Ikeda, Takaya, et al.
Publicado: (2020)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study
por: Akagi, Kazumasa, et al.
Publicado: (2022)

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis
por: Takemoto, Shinnosuke, et al.
Publicado: (2021)

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
por: Tomono, Hiromi, et al.
Publicado: (2023)

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
por: Dotsu, Yosuke, et al.
Publicado: (2020)

Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non‐squamous non‐small cell lung cancer
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases
por: Ogata, Ryosuke, et al.
Publicado: (2022)

Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy
por: Takemoto, Shinnosuke, et al.
Publicado: (2023)

Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma
por: Umeyama, Yasuhiro, et al.
Publicado: (2023)

Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia‐inducible factor‐1α, vascular endothelial growth factor, and hypervascularization
por: Tagawa, Ryuta, et al.
Publicado: (2023)

Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring
por: Gyotoku, Hiroshi, et al.
Publicado: (2020)

Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets
por: Shimada, Midori, et al.
Publicado: (2023)

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
por: Taniguchi, Hirokazu, et al.
Publicado: (2021)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Pulmonary Artery Sarcoma Overexpressing Platelet-derived Growth Factor Receptor α
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction
por: Shimada, Midori, et al.
Publicado: (2017)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
por: Makino, Yoshinori, et al.
Publicado: (2019)

Primary Mediastinal Large B-cell Lymphoma Exhibiting Endobronchial Involvement
por: Shimada, Midori, et al.
Publicado: (2016)

Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding
por: Tomono, Hiromi, et al.
Publicado: (2019)

Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum
por: Sumiyoshi, Makoto, et al.
Publicado: (2017)

Onset of pulmonary Epstein–Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis
por: Ogata, Ryosuke, et al.
Publicado: (2021)

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011)

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
por: Ogawara, Daiki, et al.
Publicado: (2017)

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M
por: Ogawara, Daiki, et al.
Publicado: (2017)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy
por: Senju, Hiroaki, et al.
Publicado: (2018)

Vildagliptin‐induced ground‐glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation
por: Tanaka, Yasuhiro, et al.
Publicado: (2020)

Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors
por: Dotsu, Yosuke, et al.
Publicado: (2022)

Exploring the ethical complexities of do‐not‐attempt‐resuscitation orders using the approach of advance care planning
por: Ogata, Ryo, et al.
Publicado: (2023)

Birth Cohort Effects on Incidence of Lung Cancers: A Population‐based Study in Nagasaki, Japan
por: Soda, Hiroshi, et al.
Publicado: (2000)

Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells
por: Okuno, Daisuke, et al.
Publicado: (2020)

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017)

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study
por: Soda, Hiroshi, et al.
Publicado: (2018)

Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab
por: Okamura, Kazuaki, et al.
Publicado: (2017)

Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G
por: Suyama, Takayuki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uk8norjno458tbs60cb64fv0fb